Drug intelligence / Profile preview

PBI-06150

Development stage: Preclinical
Lead developer: Phoenix Biotechnology
Modality: Small Molecules
Administration: Sublingual

Overview

PBI-06150 is a botanical drug candidate developed by Phoenix Biotechnology, consisting of a defined extract from the *Nerium oleander* plant. The extract's primary active component is oleandrin, a cardiac glycoside. PBI-06150 is being developed for the treatment of viral diseases, specifically targeting enveloped viruses like SARS-CoV-2. Its mechanism of action involves binding to and inhibiting the Na,K-ATPase enzyme, which has been shown to interfere with viral replication and progeny virion formation. Preclinical data indicates potent antiviral activity in vitro and efficacy in reducing viral loads in animal models of COVID-19.

Other names: Nerium oleander extract

Targets

ATP1A (Sodium/potassium-transporting ATPase)

Beyond the preview

Go deeper on PBI-06150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBI-06150.

Explore the full profile